Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple ...

Novartis Pharma AG: Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy

In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple ...
EuropaWire

Novartis Reports Final Phase III ALIGN Results Supporting Kidney Function Benefit of Vanrafia in IgA Nephropathy

(PRESS RELEASE) BASEL, 13-Feb-2026 — / EuropaWire / — Novartis has announced final Phase III results from the ALIGN study evaluating Vanrafia (atrasentan) in adults with IgA nephropathy (IgAN), ...